RxDoctor Payments Data

Maria Herrera, MD

Pulmonary Disease · Longmont, CONPI 1952627473

Payments from drug & device makers

$1,480in general payments, 2019–2025

Across 24 payments — averaging $61.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$622
  • Boehringer Ingelheim$280
  • Grifols USA, LLC$174
  • Daiichi Sankyo Inc.$125
  • Abbott$112
  • GSK$86
  • plus $81 from 3 others

What the payments were for

  • Food & beverage$1,480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,480 in reported general payments places this provider in the 55th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$70,313
Medicare patients
239
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter228$185,262
Spiriva RespimatTiotropium Bromide130$73,028
Fasenra PenBenralizumab11$66,759
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$51,841
Stiolto RespimatTiotropium Br/Olodaterol Hcl80$41,171
SymbicortBudesonide/Formoterol Fumarate78$26,963
Advair HfaFluticasone Propion/Salmeterol34$15,591
Breo ElliptaFluticasone/Vilanterol32$13,773
Incruse ElliptaUmeclidinium Bromide16$5,674
Combivent RespimatIpratropium/Albuterol Sulfate11$5,550
Varenicline Tartrate21$5,449
BreynaBudesonide/Formoterol Fumarate27$4,977
Albuterol Sulfate HfaAlbuterol Sulfate150$4,226
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$3,506
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$86$204,709276 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$280$119,750221 claims
AstraZenecaBreztri Aerosphere, Symbicort$622$78,804133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Longmont

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →